Basic Information
SOLU-MEDROL FOR INJECTION 500 mg/8 ml
INJECTION, POWDER, FOR SOLUTION
Regulatory Information
SIN04683P
June 13, 1990
Prescription Only
Therapeutic
INTRAVENOUS, INTRAMUSCULAR
August 10, 2023
May 30, 2025
XH02AB04
Company Information
Active Ingredients
Strength: 500 mg/8 ml
Detailed Information
Contraindications
**4.3 Contraindications** Methylprednisolone sodium succinate is contraindicated: - In patients who have systemic fungal infections. - In patients with known hypersensitivity to methylprednisolone or any component of the formulation. - For use by the intrathecal route of administration. - For use by the epidural route of administration. Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids.
Indication Information
**4.1 Therapeutic Indications** Methylprednisolone sodium succinate is indicated in the following conditions: **Endocrine Disorders** - primary or secondary adrenocortical insufficiency (in conjunction with mineralocorticoids, where applicable); - acute adrenocortical insufficiency (mineralocorticoid supplementation may be necessary); - shock secondary to adrenocortical insufficiency, or shock unresponsive to conventional therapy when adrenal cortical insufficiency may be present (when mineralocorticoid activity is undesirable); - pre-operatively, or in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful; - congenital adrenal hyperplasia; - non-suppurative thyroiditis; - hypercalcemia associated with cancer. **Rheumatic Disorders** (as adjunctive therapy for short-term administration in the management of an acute episode or exacerbation) - post-traumatic osteoarthritis; - synovitis of osteoarthritis; - rheumatoid arthritis, including juvenile rheumatoid arthritis; - acute and subacute bursitis; - epicondylitis; - acute non-specific tenosynovitis; - acute gouty arthritis; - psoriatic arthritis; - ankylosing spondylitis. **Collagen Diseases and Immune Complex Diseases** (during an exacerbation or as maintenance therapy in selected cases) - systemic lupus erythematosus (and lupus nephritis); - acute rheumatic carditis; - systemic dermatomyositis (polymyositis); - polyarteritis nodosa; - Goodpasture's syndrome. **Dermatologic Diseases** - pemphigus; - severe erythema multiforme (Stevens-Johnson syndrome); - exfoliative dermatitis; - severe psoriasis; - bullous dermatitis herpetiformis; - severe seborrheic dermatitis; - mycosis fungoides. **Allergic States** (to control severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment) - bronchial asthma; - contact dermatitis; - atopic dermatitis; - serum sickness; - drug hypersensitivity reactions; - urticarial transfusion reactions; - acute non-infectious laryngeal edema. **Ophthalmic Diseases** (severe acute and chronic allergic and inflammatory processes involving the eye) - herpes zoster ophthalmicus; - iritis, iridocyclitis; - chorioretinitis; - diffuse posterior uveitis and choroiditis; - optic neuritis; - sympathetic ophthalmia. **Gastrointestinal Diseases** (to manage critical periods of the disease) - ulcerative colitis; - regional enteritis. **Respiratory Diseases** - symptomatic sarcoidosis; - berylliosis; - fulminating or disseminated tuberculosis (when used concurrently with appropriate antituberculous chemotherapy); - Loeffler's syndrome not manageable by other means; - aspiration pneumonitis. **Hematologic Disorders** - acquired (autoimmune) hemolytic anemia; - idiopathic thrombocytopenic purpura in adults; - secondary thrombocytopenia in adults; - erythroblastopenia (RBC anemia); - congenital (erythroid) hypoplastic anemia. **Neoplastic Diseases** (palliative management) - leukemias and lymphomas in adults; - acute leukemia of childhood. **Edematous States** - To induce diuresis or remission of proteinuria in the nephrotic syndrome without uremia. **Nervous System** - cerebral edema from primary or metastatic tumors, or surgical or radiation therapy; - acute exacerbations of multiple sclerosis; - acute spinal cord injury. The treatment should begin within 8 hours of injury. **Other Indications** - tuberculous meningitis with subarachnoid block or impending block (when used concurrently with appropriate antituberculous chemotherapy); - trichinosis with neurologic or myocardial involvement; - organ transplantation; - prevention of nausea and vomiting associated with cancer chemotherapy.